A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. (2018)
Attributed to:
Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.484
PubMed Identifier: 29438361
Publication URI: http://europepmc.org/abstract/MED/29438361
Type: Journal Article/Review
Volume: 118
Parent Publication: British journal of cancer
Issue: 6
ISSN: 0007-0920